U.S. should review drugmakers' opioid settlement tax breaks -House panel

1 minute read
Register now for FREE unlimited access to Reuters.com

WASHINGTON, March 14 (Reuters) - The U.S. Justice and Treasury Departments should review the tax deductions four drugmakers made related to their $26 billion opioid settlement, the U.S. House Oversight and Reform Committee said in a statement on Monday.

The lawmakers, in a letter dated March 10, asked the departments to examine the tax breaks taken by Cardinal Health Inc(CAH.N), McKesson Corp (MCK.N), AmerisourceBergen Corp (ABC.N) and Johnson &Johnson (JNJ.N).

Register now for FREE unlimited access to Reuters.com
Reporting by Susan Heavey; Editing by Katharine Jackson

Our Standards: The Thomson Reuters Trust Principles.